Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Anaplastic Lymphoma Kinase (ALK) gene, as a tyrosine kinase closely related to tumors, can be activated by translocation or mutation. Abnormal expression such as gene mutation, rearrangement and amplification can activate cell signal transduction in the body. Pathway, which regulates the growth, differentiation and migration of tumors. Tyrosine kinases are kinases that enzymatically catalyze the transfer of gamma phosphate groups from adenosine triphosphate to target proteins. They can catalyze the phosphorylation of protein tyrosine residues on a variety of substrates, and play an important role in cell growth, proliferation, and differentiation. The main oncology indications for tyrosine kinase inhibitors (TKI) include solid tumors and leukemia.
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Leukemia and Solid Tumor are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, ALK Tyrosine Kinase Inhibitors (ALK-TKIs) key companies include Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding and Chugai Pharmaceutical Co, etc. Pfizer, Nuvartis, Takeda are top 3 players and held % share in total in 2022.
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) can be divided into Crizotinib, Alectinib, Ceritinib and Brigatinib, etc. Crizotinib is the mainstream product in the market, accounting for % share globally in 2022.
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) is widely used in various fields, such as Leukemia, Solid Tumor, Lung Cancer and Others, etc. Leukemia provides greatest supports to the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) industry development. In 2022, global % share of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) went into Leukemia filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Pfizer
Nuvartis
Takeda
Betta Pharma
Shouyao Holding
Chugai Pharmaceutical Co
Segment by Type
Crizotinib
Alectinib
Ceritinib
Brigatinib
Lorlatinib
Ensartinib
CT-707
Leukemia
Solid Tumor
Lung Cancer
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, ALK Tyrosine Kinase Inhibitors (ALK-TKIs) introduction, etc. ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Leukemia and Solid Tumor are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for ALK Tyrosine Kinase Inhibitors (ALK-TKIs) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, ALK Tyrosine Kinase Inhibitors (ALK-TKIs) key companies include Pfizer, Nuvartis, Takeda, Betta Pharma, Shouyao Holding and Chugai Pharmaceutical Co, etc. Pfizer, Nuvartis, Takeda are top 3 players and held % share in total in 2022.
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) can be divided into Crizotinib, Alectinib, Ceritinib and Brigatinib, etc. Crizotinib is the mainstream product in the market, accounting for % share globally in 2022.
ALK Tyrosine Kinase Inhibitors (ALK-TKIs) is widely used in various fields, such as Leukemia, Solid Tumor, Lung Cancer and Others, etc. Leukemia provides greatest supports to the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) industry development. In 2022, global % share of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) went into Leukemia filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
Nuvartis
Takeda
Betta Pharma
Shouyao Holding
Chugai Pharmaceutical Co
Segment by Type
Crizotinib
Alectinib
Ceritinib
Brigatinib
Lorlatinib
Ensartinib
CT-707
Segment by Application
Leukemia
Solid Tumor
Lung Cancer
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, ALK Tyrosine Kinase Inhibitors (ALK-TKIs) introduction, etc. ALK Tyrosine Kinase Inhibitors (ALK-TKIs) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of ALK Tyrosine Kinase Inhibitors (ALK-TKIs) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices